The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer
- PMID: 15698733
- DOI: 10.1016/j.ejso.2004.09.007
The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer
Abstract
Aim: Serum tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and CA242 were investigated to evaluate the values of single and combined test in the diagnosis and prognosis of pancreatic cancer.
Methods: Pre-operative serum CEA, CA19-9 and CA242 were measured in 105 pancreatic cancers, 70 non-pancreatic malignancies and 30 benign pancreatic diseases.
Results: The sensitivity of CA19-9 alone was the highest in pancreatic cancer patients (80%), but the specificity was significantly lower than that of CEA and CA242 (P<0.01). The combination of CEA and CA242 could increase the specificity to 92%. In serum CA242 positive patients, the survival time was remarkably shorter than that of patients with negative result (P<0.01). The survival time in patients with more than two markers positive expression of CEA, CA19-9 and CA242 was obviously shorter than that of only one or no marker positive expression (P<0.05).
Conclusion: The diagnostic rate of CA19-9 in pancreatic cancer is better than that of CEA and CA242. Combined detection of CEA and CA242 can improve the diagnostic specificity obviously. High levels of serum markers are associated with advanced stage of the disease. Patients with two or three markers positive expression of CEA, CA19-9, and CA242 simultaneously had a shorter survival time.
Similar articles
-
Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.Chin J Dig Dis. 2006;7(3):170-4. doi: 10.1111/j.1443-9573.2006.00263.x. Chin J Dig Dis. 2006. PMID: 16808798
-
[Detection and clinical study of serum tumor markers in patients with colorectal cancer].Zhonghua Zhong Liu Za Zhi. 2005 May;27(5):286-8. Zhonghua Zhong Liu Za Zhi. 2005. PMID: 15996321 Chinese.
-
Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):464-8. Hepatobiliary Pancreat Dis Int. 2004. PMID: 15313690
-
[Tumor markers for pancreatic and biliary tract cancer].Gan To Kagaku Ryoho. 2004 Sep;31(9):1443-6. Gan To Kagaku Ryoho. 2004. PMID: 15446574 Review. Japanese.
-
[Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].Pol Merkur Lekarski. 2002 Jan;12(67):77-80. Pol Merkur Lekarski. 2002. PMID: 11957811 Review. Polish.
Cited by
-
Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma.J Gastrointest Cancer. 2013 Dec;44(4):404-9. doi: 10.1007/s12029-013-9512-8. J Gastrointest Cancer. 2013. PMID: 23765155
-
Prognostic factors in resectable cholangiocarcinoma patients: Carcinoembryonic antigen, lymph node, surgical margin and chemotherapy.World J Gastrointest Oncol. 2013 Apr 15;5(4):81-7. doi: 10.4251/wjgo.v5.i4.81. World J Gastrointest Oncol. 2013. PMID: 23671735 Free PMC article.
-
Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer.World J Surg Oncol. 2012 May 4;10:77. doi: 10.1186/1477-7819-10-77. World J Surg Oncol. 2012. PMID: 22559838 Free PMC article.
-
LncRNAs in pancreatic cancer.Oncotarget. 2016 Aug 30;7(35):57379-57390. doi: 10.18632/oncotarget.10545. Oncotarget. 2016. PMID: 27429196 Free PMC article. Review.
-
The Significance of Liquid Biopsy in Pancreatic Cancer.J Cancer. 2018 Sep 8;9(18):3417-3426. doi: 10.7150/jca.24591. eCollection 2018. J Cancer. 2018. PMID: 30271504 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical